Singapore General Hospital Department of Orthopaedics
Singapore
NCT Number: NCT07455591
This study is conducted as a pilot trial to assess the added benefit of the VeraSeal fibrin sealant to TXA on postoperative outcomes following TKR. Informed consent is obtained from all participants prior to inclusion in the study. Patients are prospectively recruited from a consecutive series of TKR procedures performed for end-stage osteoarthritis. Recruited patients were randomised into two cohorts: those receiving intra-articular tranexamic acid (TXA) alone, and those receiving intra-articular TXA and VeraSeal fibrin sealant (TXA+Sealant). Randomisation is performed just prior to surgery using a digital random allocation generator by the surgical team. Patients and physiotherapists responsible for outcome data collection are blinded to group allocation throughout the study period.
Intraoperative administration of the sealant is performed after prosthetic implantation, which was followed by topical intra-articular TXA. In the TXA group, TXA is applied intraoperatively into the joint capsule prior to closure. In the TXA+Sealant group, VeraSeal was applied evenly onto subcutaneous tissues, synovium and exposed bony surfaces within the joint capsule and allowed to cure. The same dose of topical TXA was infiltrated after VeraSeal had cured, prior to closure. All other pathways were standard per hospital protocols.
Preoperatively, demographic data including age, sex, height, and weight, as well as serum haemoglobin (Hb) levels were collected for all patients. Primary outcomes were collected on postoperative day 1: serum Hb, knee flexion range of motion (°), ambulation distance (m), and rest and ambulatory pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain) were collected. All patients were inpatient during primary outcome data collection. Secondary outcomes included: Oxford Knee Score (0-48, higher is better), American Knee Society Score (0-100, higher is better), and SF-36 Score (0-100, higher is better), collected pre-operatively and 6 months post-operatively.
Looking for future studies?
Notify Me21 year and older
All sexes
Interventional
Phase 4
Singapore
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Fibrin sealant contains human thrombin and fibrinogen, aiding platelet activation, aggregation, and fibrin clot formation.
Topical Tranexamic Acid (TXA) is an antifibrinolytic agent which stabilises clot formation and is infiltrated into local tissues perioperatively prior to closure.
Time frame: Preoperatively and one day after surgery
Serum Haemoglobin (g/dL)
Time frame: Preoperatively and one day after surgery
Knee flexion range of motion (°)
Time frame: One day after surgery
Ambulation distance (m)
Time frame: One day after surgery
Rest pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain)
Time frame: One day after surgery
Ambulatory pain visual analogue scales (VAS) between 0 (no pain) and 10 (worst pain)
Time frame: Pre-operatively and 6 months post-operatively
Oxford Knee Score (0-48, higher is better)
Time frame: 6 months post-operatively
American Knee Society Score (0-100, higher is better)
Time frame: 6 months post-operatively
SF-36 Score (0-100, higher is better)
Time frame: Preoperatively
Age in years
Time frame: Preoperatively
Sex
Time frame: Preoperatively
Height and weight summarised to BMI (kg/m2)
Singapore General Hospital
Other
A Prospective Randomised Pilot Trial Of The Supplemental Use Of Intraoperative Fibrin Sealant Alongside TXA On Postoperative Recovery After Total Knee Replacement
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07630259
Arthritis, Joint Diseases
Santiago, Santiago Metropolitan, Chile
View Trial DetailsNCT07437716
Apnea, Arthritis
Kafr ash Shaykh, Egypt
View Trial DetailsNCT01456611
Osteo Arthritis of the Knee
Birmingham, Alabama, United States
View Trial DetailsNCT07736781
Arthritis, Joint Diseases
Kota Bharu, Kelantan, Malaysia
View Trial Details